Compare Alcon AG (ALC) vs Okta, Inc. (OKTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Okta, Inc. — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Okta, Inc. trades at $145.99 (market cap $25.81B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| ALC | OKTA | |
|---|---|---|
Market Cap | $32.69B | $25.81B |
Sector | Health | Technology |
52-Week High | $92.22 | $148.60 |
52-Week Low | $62.02 | $62.93 |
Enterprise Value | $36.28B | $23.63B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
OKTA trades at $148.47, up 4.99% on the day, with strong technical momentum and bullish moving averages. The company reported revenue of $2.61B in 2025, achieving profitability with net income of $28M after years of losses. Recent earnings beats and AI-driven demand have fueled investor optimism, though valuation multiples remain elevated.
Outlook is positive with robust revenue growth and improving margins, but high P/E of 107.68 poses valuation risk. Analyst consensus is bullish with 72.55% buy ratings, though price target of $121.08 suggests caution near current levels. Key risks include competition and execution on AI monetization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
